Pre-existing and early cellular immune factors correlate with functionally complete protection against primary controlled human SARS-CoV-2 infection
- PMID: 41354730
- DOI: 10.1038/s41467-025-67017-8
Pre-existing and early cellular immune factors correlate with functionally complete protection against primary controlled human SARS-CoV-2 infection
Abstract
Identifying host factors that mediate protection against newly-emergent viruses is needed for improved pandemic preparedness. Here, we analysed pre- and early post-exposure immune factors associated with resisting SARS-CoV-2 infection after human challenge in seronegative individuals, using multiplex protein, cytometric and RNA sequencing approaches in the nasopharynx and circulation. Pre-existing cross-reactive antibodies correlate poorly with clinical outcome. Instead, protection is associated with heightened nasopharyngeal CCL13 levels locally produced by conventional dendritic cells and monocytes, along with cross-reactive T cells and less differentiated NK cells. Conditional independence network analysis implicates nasal CCL13 as the central node connected to pre-existing non-structural protein-specific T cells by CD1c+ DCs. In those who became infected, baseline cross-reactive T cell and less differentiated NK cell frequencies also correlate with shorter infection duration. Thus, pre-existing mucosal chemokine levels may promote rapid innate and innate-like responses that effectively block infection. ClinicalTrials.gov identifier NCT04865237.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: A.M. and A.C. hold shares in hVIVO Services Ltd. In the past 3 years, S.A.T. has received remuneration for scientific advisory board membership from Sanofi, GlaxoSmithKline, Foresite Labs and Qiagen. S.A.T. is a co-founder and holds equity in Transition Bio and Ensocell. From 8 January 2024, S.A.T. is a part-time employee of GlaxoSmithKline. P.O. declares remuneration for scientific advisory boards from Sanofi, AstraZeneca, GlaxoSmithKline, Pfizer, Seqirus, Moderna, BioNet Asia, Shionogi and IntegerBio. J.S.T. serves on the scientific advisory boards of CytoReason, ImmunoScape, and Snow Medical. All other authors declare no competing interests.
References
-
- Barnes, M. V. C., Mandla, A., Smith, E., Maskuniitty, M. & Openshaw, P. J. M. Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022. Immunother. Adv. 3, ltad024 (2023).
-
- Killingley, B. et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat. Med. 28, 1031–1041 (2022).
-
- Lindeboom, R. G. H. et al. Human SARS-CoV-2 challenge uncovers local and systemic response dynamics. Nature 631, 189–198 (2024).
-
- Ratcliffe, H. et al. Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents. iScience 26, 108500 (2023).
-
- Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID−19 patients. Cell Rep. 34, 108728 (2021).
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
